FOUNDING INDIVIDUALS

Frank KungManaging Partner
Vivo Capital

Dr. Kung is a founding member of Vivo Capital (formerly BioAsia Investments), a healthcare/biotechnology venture capital management firm in Palo Alto, California.
Dr. Kung started his career in the biotechnology industry in 1979 when he joined Cetus Corporation. He later co-founded Cetus Immune Corporation in 1981, which was acquired by its parent company in 1983. In 1984 he co-founded Genelabs Technologies, Inc. (NADSAQ: GNLB) where he served as Chairman and CEO until 1995. During his tenure in Genelabs, he brought the company public in 1991, and built it to a 175 employee international biotech company with operations in the United States, Belgium, Singapore, Switzerland and Taiwan.
Dr. Kung received his B.S. in chemistry from the National Tsing Hua University in Taiwan, his Ph.D. in molecular biology and M.B.A. from the University of California, Berkeley. He received the Best Use of Technology Award from the Governor of California, the Entrepreneur of the Year Awards from Ernst and Young, and the Asian Business League. He also served on the board of directors of the Emerging Company Governing Body of the Biotechnology Industry Organization (BIO); Mt. Jade Science and Technology Association, West Coast; and the Asian American Manufacturing Association. He was appointed by the U.S. Secretary of Health and Human Services as a voting member of the National Biotechnology Policy Board. Dr. Kung currently serves on the board of directors of a number of emerging healthcare and biotechnology companies.

Hongbo LuPartner
Lilly Asia Ventures

Dr. Lu Hongbo is currently the Lilly Asia Fund partner. Former OBO capital (OrbiMed Advisor) Asia Pacific managing director, Piper Jaffray& Co. (Piper Jaffray) executive director, and in the United States of California life science and technology research and development of protein chip Zyomyx is responsible for business development. Dr. Lu is a graduate of Tsinghua University, Beijing, and received a doctorate in biomedical engineering from University of Washington and University of California at Berkeley MBA.

James LiCEO
JW Therapeutics

Currently James has been focusing on investing and building new life science companies that brings in cross-board breakthrough technologies and disruptive business models in China.
Until June 2015, Dr. James Li was a Vice President and the founding General Manager of Amgen China, where he led the company’s efforts in formulating a China entry strategy and established its presence in China to help patients gaining access to Amgen’s vital medicines.
Prior to joining Amgen, James was a Partner at Kleiner Perkins Caufield & Byers life science practice, worked both in the US and China funds. He successfully invested in a number of companies both in the US and China.
From 1991 to 2006, James spent over 15 years with Merck Co. & Inc. where he held leadership positions with increasing responsibilities in clinical research, regulatory affairs, new product development and franchise management, both in the US and Asia Pacific/China. During his tenure, he was instrumental in obtaining regulatory approvals of Merck vaccines across Asia Pacific Region when the Vaccine Division started operations in the region, successfully built the foundations of Merck’s medical operations in China and drove the success of Merck’s anti-hypertension franchise in Asia.
James received his Medical Degree from Shanghai Medical University followed by a Master of Science degree in Microbiology from the University of Montana.

Norman Chen Venture Partner
6 Dimensions Capital

Mr. Chen began his healthcare career at Baxter International, where he was responsible for the kidney dialysis business unit across Asia. In 1995, Mr. Chen founded Asia Renal Care, Ltd. to provide international-standard dialysis services in Asia, and led the company to become the leading independent dialysis group in Asia with over 70 centers in Taiwan, Singapore, the Philippines, Japan, Korea and Malaysia.

In 2002, Mr. Chen joined Walden International as Entrepreneur-in-Residence. In 2004, he co-founded DeltaHealth as a provider of international-quality cardiovascular care in China. DeltaHealth opened its first clinic in Shanghai in 2010 and a 200-bed cardiovascular hospital in 2016.

From 2005-2012, Mr. Chen led healthcare investing at Fidelity Growth Partners Asia (now called Eight Roads Ventures), where he was responsible for investments in several successful companies in China in the CRO, specialty pharmaceutical, medical device, medical service and other healthcare areas.

Mr. Chen is a Venture Partner at 6 Dimensions Capital, a leading US-China life sciences fund with $1 billion under management.

Mr. Chen is on the boards or advisory councils of the following non-profit organizations – Children’s Medical Foundation (HK), Marine Science Institute, and Positive Coaching Alliance.

Mr. Chen has a BS degree in Biology from the Massachusetts Institute of Technology and an MBA from Stanford University. He lives in the SF Bay Area.

Marietta Wu,Managing Director,
Quan Capital

Dr. Marietta Wu’s experience ranges from clinical medicine and medical research to finance and entrepreneurship. She is currently Managing Director of Quan Capital, a premier life sciences venture fund backed by Zai Lab. She is a co-founder of Zai Lab and served as COO of the company. Prior to founding Zai Lab, she was Managing Director at Burrill & Company, leading Burrill’s investments and operation in Greater China, focusing on venture capital investing in China and Taiwan related life sciences opportunities. She serves on the board of Jing Medicine Technology, Kira Pharmaceutical and Qiagen (Suzhou) Translational Medicine Company, and was a board member of JHL Biotech(TWEM: 6540), Taiwan Liposome Company (GTSM: 4152) and General Biologics Corporation (TWEM: 4117). She also served as acting COO of Waterstone, a specialty pharmaceutical company with key operations in China. Over the past decade, she has been active in cross border ventures and value creation in the life sciences industry. Dr. Wu is a frequent speaker and author on China and Taiwan life sciences topics, and a founding member of the China Healthcare Investment Conference

Prior to her focus in healthcare investments, Dr. Wu was Director of Strategy at Edwards Lifesciences. She also held various financial and business development positions at Eli Lilly & Company.

Dr. Wu received her medical degree from Shanghai Jiaotong University School of Medicine (formerly Shanghai Second Medical University), a Ph.D. in Medical Sciences from Medical College of Ohio, and an MBA from the University of Michigan Ross School of Business.

ORGANIZING COMMITTEE

Norman Chen Venture Partner, 6 Dimensions Capital
Frank KungManaging Partner, Vivo Capital
James Li CEO, JW Therapeutics
Hongbo LuPartner, Lilly Asia Ventures
Marietta WuManaging Director, Quan Capital
Cyber Cao Managing Director
Sequoia Capital China

Prior to joining Sequoia, Cyber participated most of the investment starting from Vivo Fund VII in China and served on the board of SMC and Gengmei APP. Before that, Cyber was the leader of Nycomed North Asia strategy and business development, and He helped Nycomed refurbish its China business and played an integral role in its acquisition of Techpool, a leading Chinese pharmaceutical player. In his early career, Cyber was at McKinsey & Company where he worked with both multi-national and local pharmaceutical companies on corporate strategy. Cyber received his M.S. in Pharmacy Administration and a B.S. in Pharmaceutics from Peking University.

Jon Liong Managing Director
Lychee Group

Jon is the Founder and Managing Partner of Lychee Group, a company focused on creating the highest-quality events for China's life sciences industry.
Jon brings over 15 years of success in the strategic planning, organization and marketing of pharmaceutical and biotech business-to- business conferences.
In 1999, he joined Strategic Research Institute, a leading New York- based conference company. During his tenure there he organized and directed over 100 successful life sciences conferences and managed the production of over 40 events annually. As Managing Director, Jon led the company’s global expansion into China, conceiving and launching the "IMPACT CHINA: Pharmaceutical Global R&D" series, which was the first ever Western-organized conference covering China's life sciences industry.
Since starting Lychee, Jon has helped launch some of the highest profile healthcare events in China including "China Healthcare Investment Conference (CHIC)," "ChinaTrials: Global Clinical Development Summit," and "Asia Healthcare CEO Meeting by OrbiMed." Jon received his B.S. in Marketing from the New York University Stern School of Business.

Karen Wong Partner
Wilson Sonsini Goodrich & Rosati

Dr. Karen Wong is a life sciences IP partner at Wilson Sonsini Goodrich & Rosati. Her practice includes freedom- to-operate and due-diligence studies, patent preparation and prosecution, opinion work, litigation strategy, and technology licensing. Karen serves as IP counsel to many venture-backed companies, and has worked on numerous major strategic alliance transactions, acquisitions, spin-outs, and IPOs. Dr. Karen Wong is a life sciences IP partner at Wilson Sonsini Goodrich & Rosati. Her practice includes freedom- to-operate and due-diligence studies, patent preparation and prosecution, opinion work, litigation strategy, and technology licensing. Karen serves as IP counsel to many venture-backed companies, and has worked on numerous major strategic alliance transactions, acquisitions, spin-outs, and IPOs.
Prior to practicing law, Karen conducted doctoral and post-doctoral research at Harvard and Tufts Medical School in molecular biology, cell biology, and physiology. Karen is a co-founder and board member of BioE2E, which has built one of the largest communities of life sciences entrepreneurs in the Bay Area. A native of Sichuan, China, she is fluent in English, Mandarin, and Cantonese.

Chen Yu Managing Partner
Vivo Capital

Chen Yu, M.D., M.B.A. is a Managing Partner based in Palo Alto who joined Vivo in 2004. At Vivo, Dr. Yu invests in both private and public pharmaceutical and medical device companies in the US and China. Dr. Yu has extensive operating experience with leadership roles at both private and public companies, including Sagent Pharmaceuticals (SGNT), China KangHui (KH), and aQuantive (AQNT). Notably, Dr. Yu has played a leading industry role in facilitating cross border deals between emerging market and US healthcare companies. As Chief Business Officer at China KangHui (KH), a leading China based orthopedic company, he helped take the company public on the New York Stock Exchange in 2010 and ultimately led negotiations during the sale to Medtronic for $816 MM in 2012. Most recently, Dr. Yu served as Chief Operating Officer at Sagent Pharmaceuticals (SGNT), which partners with leading companies across Asia and Europe. Dr. Yu currently serves or has served on the boards of several life science companies in both the US and China, including Sentre Heart (US), Rempex (Acquired by MDCO), Nora Therapeutics (US), Jian Rui Bao (China), GMT Medical (China), and Synaptic Medical (China). Other representative investments include Trauson (acquired by Stryker for $764 MM), Durata (acquired by Actavis for $800 MM), Achillion (ACHN), Cubist (CBST), and Ocera (OCRX).
Dr. Yu is also active in the community and currently serves on the California Leadership Council for the Nature Conservancy, an environmental non-profit with global reach. He was also previously a member of the Stanford Medical School Alumni Board of Governors. Dr. Yu received his M.D. and M.B.A. from Stanford University and graduated magna cum laude with a B.A. in Biology from Harvard University.

HOME - ABOUT - AGENDA - SPEAKERS - FOUNDERS - SPONSORS - PARTNERS - VENUE - CONTACT

Copyright © 2017 Consortium of China Healthcare. All rights reserved